Joy Duemke: Optimizing Stem Cell Collection for Gene Therapy Success
Joy Duemke, Director of Marketing and Commercialization in North America at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“Gene therapy is creating new possibilities for patients with genetic hemoglobinopathies, but collecting sufficient, high-quality hematopoietic progenitor cells (HPCs) can be particularly challenging due to the impact of the underlying disease on mobilization.
Optimizing these procedures is an important step in helping more patients benefit from these therapies.
We appreciate AABB and presenting faculty, including Dr. John Manis, behind ‘Optimizing Apheresis Starting Material Collections for Stem Cell Gene Therapy Manufacturing for Patients with Genetic Hemoglobinopathies’ for tackling these challenges head-on to help ensure more SCD and thalassemia patients can benefit from these breakthrough therapies.
Register for the program on Wednesday, August 12, from 2:00–3:00 PM ET.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 02:28N. Mariana S. Vasquez: Warm vs Cold Autoimmune Hemolytic Anemia for USMLE/NBME Questions
-
Sep 4, 2026, 22:03Maeve Crowley: Haemophilia Treatment Over the Decades and Hope for the Future
-
Sep 4, 2026, 22:01Lama Skieker: Understanding Thrombocytopenia in Malaria
-
Sep 4, 2026, 22:00Hiten Patel: How an IVC Filter Helps Prevent Pulmonary Embolism
-
Sep 4, 2026, 21:54Gianluca Costamagna: Investigating the Link Between Cancer and Acute Ischemic Stroke
-
Sep 4, 2026, 21:50Ben Creagh-Brown: PRAGUE-26 and HI-PEITHO Similar Benefits With Important Differences
-
Sep 4, 2026, 21:48Jin-Xiong She: Homocysteine beyond Heart Disease – The Methylation-Mobility Connection
-
Sep 4, 2026, 21:44Aravind Palraj: Anemia of Chronic Inflammation is Not Just “Iron Deficiency”
-
Sep 4, 2026, 21:41Chokri Ben Lamine: Fundamental HSCT Workshop for Hematology Fellows at HAAG 2026